James Cox is the visionary CEO and Founder of BioTalent, a company he launched in 2018 to revolutionise STEM recruitment. With a passion for science, sales, and connecting exceptional talent with pioneering organisations, James has led BioTalent to become a trusted partner in the life sciences sector. His leadership is defined by a commitment to innovation, excellence, and fostering growth within the global STEM landscape.
Before founding BioTalent, James honed his expertise at Hobson Prior, where he achieved record-breaking permanent billings and played a pivotal role in expanding the Acacium Group's global footprint. In 2023, James spearheaded BioTalent’s acquisition by The IN Group, creating a global specialist division with over 60 experts dedicated to solving the talent shortage in life sciences.
Outside of work, James cherishes time with his wife and two young children. A sports enthusiast, he’s often found on the tennis court, skiing down mountains, or capturing moments as a passionate amateur photographer - a craft he once pursued professionally, with his work featured in Red Bull publications and F1 events.
Blogs by James
Why the seed funding slowdown is a talent problem, not just a funding one.
Seed funding in life sciences is down 44% year on year, and BioTalent explains why that funding gap points to a hiring gap a few years out.
The biotech market is back. The early-stage ecosystem isn't
BioTalent CEO James Cox analyses 14 months of biopharma financing data, revealing a widening gap between late-stage capital and early-stage funding.
BioTalent launches BioX: Executive search built for life sciences leadership
BioTalent launches BioX, a dedicated executive search service for life sciences, delivering 98.9% one-year retention and a fixed-fee model.
Generative AI in Biopharma Manufacturing: Hype or Game Changer?
James Cox on what four industry roundtables revealed about generative AI's real impact on biopharma manufacturing, and the looming talent gap.
What Makes BioTalent Stand Out in Today's Market?
James Cox on what senior leaders really want from a recruitment partner, and how BioTalent's model is built around that insight.
Investing in innovation: The race for biotech talent in 2025
James Cox on the NSCEB report's biotech talent findings critical skills gaps, global competition, and what it means for US leadership.
The Bounce Back for Life Sciences: What to Expect in 2025
BioTalent CEO James Cox shared his thoughts on the Life Sciences market, highlighting a promising rebound ahead.
BioTalent expands following acquisition by The IN Group
BioTalent joins The IN Group, combining with Investigo's life sciences practice to create a 50+ expert global life sciences division.
NPS Score
70+ is considered world-class
76
Get in touch
Whether you're hiring or job hunting, we're here to make the process simple. Reach out and let's talk.
All Rights Reserved 2026 BioTalent
